Patrys Ltd - ESG Rating & Company Profile powered by AI
The Sustainability score for Patrys Ltd represents the company's reporting of the UN SDGs. This analysis of Patrys Ltd employs data points from across the web and also from public disclosures by Patrys Ltd. This ESG rating includes seventeen UN SDGs including: 'No Poverty', 'Reduced Inequalities' and 'Partnerships for the Goals'.
Patrys Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.0; made up of an environmental score of 2.7, social score of 6.4 and governance score of 6.0.
5.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 724 | Skye Bioscience Inc | 5.1 | High |
| 724 | Xbrane Biopharma AB | 5.1 | High |
| 744 | Patrys Ltd | 5.0 | High |
| 744 | CSL Ltd | 5.0 | High |
| 744 | CStone Pharmaceuticals | 5.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Patrys Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Patrys Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Patrys Ltd report the average age of the workforce?
Sign up for free to unlockDoes Patrys Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Patrys Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Patrys Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Patrys Ltd offer flexible work?
Sign up for free to unlockDoes Patrys Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Patrys Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Patrys Ltd conduct supply chain audits?
Sign up for free to unlockDoes Patrys Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Patrys Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Patrys Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Patrys Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Patrys Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Patrys Ltd disclose water use targets?
Sign up for free to unlockDoes Patrys Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Patrys Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Patrys Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Patrys Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Patrys Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Patrys Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Patrys Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Patrys Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Patrys Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Patrys Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Patrys Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Patrys Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Patrys Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Patrys Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Patrys Ltd disclose its waste policy?
Sign up for free to unlockDoes Patrys Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Patrys Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Patrys Ltd disclose energy use targets?
Sign up for free to unlockDoes Patrys Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Patrys Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Patrys Ltd
These potential risks are based on the size, segment and geographies of the company.
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. The company was incorporated in 2006 and is based in Melbourne, Australia.